NSAIDs and Cell Proliferation in Colorectal Cancer
Open Access
- 24 June 2010
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 3 (7) , 2007-2021
Abstract
Colon cancer is common worldwide and accounts for significant morbidity and mortality in patients. Fortunately, epidemiological studies have demonstrated that continuous therapy with NSAIDs offers real promise of chemoprevention and adjunct therapy for colon cancer patients. Tumour growth is the result of complex regulation that determines the balance between cell proliferation and cell death. How NSAIDs affect this balance is important for understanding and improving treatment strategies and drug effectiveness. NSAIDs inhibit proliferation and impair the growth of colon cancer cell lines when tested in culture in vitro and many NSAIDs also prevent tumorigenesis and reduce tumour growth in animal models and in patients, but the relationship to inhibition of tumour cell proliferation is less convincing, principally due to gaps in the available data. High concentrations of NSAIDs are required in vitro to achieve cancer cell inhibition and growth retardation at varying time-points following treatment. However, the results from studies with colon cancer cell xenografts are promising and, together with better comparative data on anti-proliferative NSAID concentrations and doses (for in vitro and in vivo administration), could provide more information to improve our understanding of the relationships between these agents, dose and dosing regimen, and cellular environment.Keywords
This publication has 77 references indexed in Scilit:
- Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) StudyCancer Causes & Control, 2010
- Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control studyBreast Cancer Research, 2010
- Inhibition of Azoxymethane-Induced Colorectal Cancer by CP-31398, a TP53 Modulator, Alone or in Combination with Low Doses of Celecoxib in Male F344 RatsCancer Research, 2009
- A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor ActivityCancer Prevention Research, 2009
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statementThe Lancet Oncology, 2009
- Anti-Inflammatory Agents for Cancer TherapyMolecular and Cellular Pharmacology, 2009
- Sulindac suppresses β-catenin expression in human cancer cellsEuropean Journal of Pharmacology, 2008
- Aspirin blocks proliferation in colon cells by inducing a G 1 arrest and apoptosis through activation of the checkpoint kinase ATMCarcinogenesis, 2007
- Nimesulide Inhibits Crypt Epithelial Cell Proliferation at 6 Hours in the Small Intestine in CD-1 MiceDigestive Diseases and Sciences, 2007
- Cancer genes and the pathways they controlNature Medicine, 2004